Further studies are required to dissect the various mechanisms underlying UBXN2A anti-cancer functions upon its binding to mortalin and how UBXN2A-dependent inhibition of the mortalin oncoprotein pathway can alter the apoptotic efficacy of chemotherapy. Here, HSPA9 is linked to cancer.